GRTS Gritstone Bio
- 0.807
- -0.007-0.82%
Gritstone Bio News
Nature Medicine Publishes Interim Results From Gritstone Bio's Phase 1/2 Study of "Off-the-Shelf" Neoantigen Vaccine Platform (SLATE)
PDF Version -- Paper details vaccine design optimization process of Gritstone's "off-the-shelf" or shared neoantigen vaccine platform, SLATE ---- Discovery of a novel immunodominance hierarchy of
Gritstone Bio, Inc. (GRTS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors...
Gritstone Bio Presented An Update On Its T Cell Epitope Discovery Platform, EDGE, At AACR 2024, Highlighting Improvements In Prediction Of Peptide Presentation By HLA Class I, Associated With CD8+ T Cells, Since Initial Results In 2018
Gritstone Bio Presented An Update On Its T Cell Epitope Discovery Platform, EDGE, At AACR 2024, Highlighting Improvements In Prediction Of Peptide Presentation By HLA Class I, Associated With CD8+ T C
Gritstone Bio to Participate in Upcoming Investor and Scientific Conferences
PDF Version EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines
Gritstone Bio Presents Improvements to EDGE Platform at AACR 2024
PDF Version -- State-of-the-art neoantigen prediction platform (EDGE) now predicts HLA Class I presentation of epitopes with >80% accuracy ---- Newly developed EDGE-II model achieves superior pre
JMP Securities Maintains Market Outperform on Gritstone Bio, Raises Price Target to $5
JMP Securities analyst Roy Buchanan maintains Gritstone Bio (NASDAQ:GRTS) with a Market Outperform and raises the price target from $4 to $5.
Gritstone Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 316.67% JMP Securities $4 → $5 Maintains Market Outperform 03/06/2024 483.33% HC Wainwright & C
What's Going On With Small Cap Cancer Vaccine Focused Gritstone Bio Stock On Tuesday?
Tuesday, Gritstone Bio Inc (NASDAQ:GRTS) released preliminary data from the ongoing, signal-seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccin
Canopy Growth, Exact Sciences, Stereotaxis Among Healthcare Movers
Paychex, PVH And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Paychex, Inc. (NASDAQ:PAYX) to report quarter
Gritstone Bio Shares Drop 33% After Public Offering Prices
By Chris Wack Gritstone bio shares were down 33% to $1.57 in premarket trading after the company priced a $32.5 million underwritten public offering of its stock and accompanying warrants. The biote
Reported Earlier, Gritstone Bio Prices $32.5M Underwritten Public Offering Of 8,333,333 Common Stock And Accompanying Common Warrants At $1.50/Share
The offering consists of (i) 8,333,333 shares of common stock and accompanying common warrants to purchase up to 8,333,333 shares of common stock at a per share exercise price of $1.65 at a combined p
TD Cowen, Evercore ISI Acting as Book-Running Managers for Gritstone Bio Offering >GRTS
TD Cowen, Evercore ISI Acting as Book-Running Managers for Gritstone Bio Offering >GRTS
Gritstone Bio Offering to Close on or About April 4 >GRTS
Gritstone Bio Offering to Close on or About April 4 >GRTS
Gritstone Stock Plunges 35% on Mixed Phase 2 Data, Public Offering
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall
Gritstone Bio (GRTS) said Monday it had "positive" preliminary results from a phase 2 portion of a phase 2/3 trial assessing cancer vaccine Granite in metastatic microsatellite stable colorectal cance
12 Health Care Stocks Moving In Monday's After-Market Session
GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in
Gritstone Bio Starts Public Offering; Shares Drop After-Hours
Gritstone Bio (GRTS) said late Monday it has started an underwritten public offering of shares and accompanying warrants to purchase shares. The company did not provide details. TD Cowen and Evercore
Gritstone Bio Announces Proposed Public Offering
Gritstone Bio Announces Proposed Public Offering
Gritstone Bio Says Early Progression-Free Survival Trends Favor GRANITE Recipients With Hazard Ratios Of 0.82 In The Overall Population And 0.52 In A High-Risk Group, Where Clinical Data Are More Mature
Gritstone Bio Says Early Progression-Free Survival Trends Favor GRANITE Recipients With Hazard Ratios Of 0.82 In The Overall Population And 0.52 In A High-Risk Group, Where Clinical Data Are More Matu
Analysis
Price Target
No Data
